Tesamorelin – 10mg (3ml Pen)

Tesamorelin occupies a distinctive position: it is the GHRH analogue that completed the full clinical development pathway and obtained regulatory approval, on the strength of trials examining visceral adipose tissue endpoints in a specific trial population. That gives it a depth and quality of human data unmatched anywhere else in the secretagogue category, alongside a more recent research line in hepatic and cognitive endpoints.

Tesamorelin is a synthetic analogue of human GHRH(1-44) with a trans-3-hexenoyl group attached to the N-terminus, conferring resistance to dipeptidyl peptidase-4 degradation while preserving receptor activity. Research describes GHRH receptor agonism at pituitary somatotrophs producing pulsatile growth hormone release and consequent IGF-1 elevation. Clinical studies document preferential reduction in visceral relative to subcutaneous adipose tissue, an effect attributed to the lipolytic activity of physiologically patterned growth hormone secretion. Because release remains pulsatile, the literature reports IGF-1 elevation within the physiological range.

The strongest clinical evidence base of any compound in this category, including multi-centre randomised trials, long-term extension research and regulatory review documentation.

Clinical trials

Multi-centre randomised trials on visceral adipose tissue endpoints.

Hepatic research

Studies investigating liver fat fraction in metabolic dysfunction models.

Cognitive research

Trials examining cognitive endpoints in older adult populations.

Pharmacokinetics

Characterisation of N-terminal modification and DPP-4 resistance.

Regulatory record

Full clinical development documentation is publicly available.